267 results about "Lipidome" patented technology

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention relates to a construction method of a metabolic syndrome phlegm syndrome lipid metabolism characteristic diagnosis model. The construction method comprises the following steps: S1, acquiring a serum sample; s2, carrying out lipid metabolite analysis through a full-quantitative lipidomics formula; s3, carrying out primary screening on differential metabolites; s4, optimizing the characteristic indexes by using a random forest algorithm and stepwise regression; and S5, constructing a differential metabolite diagnosis model through Logistic regression analysis. By analyzing differential lipid metabolites of patients with MetS phlegm syndromes and non-phlegm syndromes, the invention reveals that abnormal accumulation of lipid and lipid metabolites may be the core pathological parenchyma of MetS phlegm syndromes. By integrating lipid metabonomics data, using a random forest algorithm, stepwise regression and other methods to screen feature difference lipid metabolites and construct a MetS phlegm syndrome specific diagnosis model, a novel combined biomarker and evidence-based basis are provided for early diagnosis of MetS phlegm syndromes, and a scientific basis can also be provided for objective diagnosis of traditional Chinese medicine phlegm syndromes.

The invention discloses an antibody-modified lipid nanoparticle, a preparation method thereof and application of the antibody-modified lipid nanoparticle as a targeting carrier. The invention provides lipid nanoparticles coupled with an antibody and loaded with nucleic acid. The lipid nanoparticles are characterized in that raw materials of the lipid nanoparticles consist of ionizable lipid, phospholipid, steroidal lipid, PEG lipid and PEG-Mal lipid, the PEG lipid is C16-PEG2k, and the PEG-Mal lipid is C16-PEG2k-Mal, and the PEG-Mal lipid is C16-PEG2k-Mal. The method aims at the key scientific problems of low delivery efficiency, insufficient targeting and the like in the field of in-vivo hematopoietic stem / progenitor cell gene therapy at present. The invention develops a lipid nanoparticle delivery system based on antibody modification, provides a modular antibody targeted delivery platform with high universality, and shows huge clinical transformation potential.

Provided herein are lipid nanoparticles composition comprising a lipid component which comprises: (i) a first ionizable cationic lipid, (ii) a PEG-lipid, wherein the PEG-lipid comprises a PEG-Ceramide. Further provided are lipid nanoparticle compositions comprising a lipid component which comprises: (i) a first ionizable cationic lipid, (ii) a PEG-lipid, wherein the PEG-lipid comprises a PEG-Ceramide selected from: N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)5000]} (C8 PEG5000-Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}(C8 PEG2000-Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)750]} (C8 PEG750-Ceramide), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)5000]} (C16 PEG5000-Ceramide), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]} (C16 PEG200-Ceramide), and N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)750]} (C16 PEG750-Ceramide) (iii) a phospholipid, and (iv) a permanently cationic lipid, an anionic lipid, or a second ionizable cationic lipid separate from the first ionizable cationic lipid.

Provided herein are lipid nanoparticles composition comprising a lipid component which comprises: (i) a first lipid wherein the first lipid is an ionizable cationic lipid, (ii) a second lipid wherein the second lipid is separate from the first lipid, (iii) a phospholipid, and (iv) a PEG-lipid wherein the second lipid is a lipid having a structural formula S-I'a, S-I'b, or S-I'c. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.

This disclosure provides a lipid composition and methods of use thereof.

The invention discloses a nucleic acid medicinal preparation based on dialkyl imidazole cationic lipid as well as a preparation method and application thereof, and belongs to the field of medicinal preparations. The nucleic acid pharmaceutical preparation comprises drug-loaded lipid nanoparticles, and the drug-loaded lipid nanoparticles comprise one or more dihydrocarbyl imidazole cationic lipids. By adjusting lipid composition and proportion in the drug-loaded lipid nanoparticles, efficient loading and delivery of different types of nucleic acid drugs can be realized; the drug-loaded lipid nanoparticles have good biological safety, the preparation process is simple, and large-scale production is easy; the drug-loaded lipid nanoparticle can effectively pass through a blood brain barrier, realizes specific brain-targeted delivery of the loaded nucleic acid drug, and provides a new strategy for realizing brain-targeted delivery of different nucleic acid drugs for treating brain diseases.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.

The invention discloses retinol retinoate-ceramide lipidosome modified by hyaluronic acid and salts thereof and a preparation method of the retinol retinoate-ceramide lipidosome, and belongs to the technical field of cosmetic nano-carriers. The preparation method comprises the steps that retinol retinoate-ceramide lipidosome is prepared, hyaluronic acid is pretreated, and the hyaluronic acid and the salts thereof are combined to prepare the retinol retinoate-ceramide lipidosome. The liposome is modified by hyaluronic acid and salts thereof in a dual-mechanism manner, and purification and stabilization are realized; the preparation method of the retinol retinoate-ceramide liposome comprises the following steps: dissolving phospholipid, a functionalized lipid component with positive ions and amino functional groups, cholesterol, retinol retinoate and ceramide in absolute ethyl alcohol to serve as an organic phase, taking a phosphate buffer solution as a water phase, dropwise adding the organic phase into the water phase under a stirring condition, stirring, performing ultrasonic treatment, washing, and drying to obtain the retinol retinoate-ceramide liposome. Performing membrane extrusion to obtain a liposome suspension; the retinol retinoate-ceramide liposome modified by hyaluronic acid and salts thereof prepared by the invention has excellent stability, skin transmittance and anti-aging and moisturizing effects, also has low irritation, and is suitable for anti-aging cosmetics.

The invention relates to a high-coverage quantitative analysis method of lipidome and a quantitative kit, the method adopts a mobile phase A and a mobile phase B with different pH values for elution, the pH value of the mobile phase B is 2.5-5, and the pH value of the mobile phase A is 2.5-3.0. According to the method, good separation of acid-sensitive lipid compounds such as PA, S1P and PS can be realized, ionization inhibition of lipid compounds such as free fatty acid and free cholesterol can be reduced, and the quantitative sensitivity of the lipid compounds can be improved. According to the method, 104 lipid subclasses can be covered, 2375 lipid compounds can be quantified, and the number of the lipid compounds is more than two times that of the lipid compounds in the existing lipidomics quantitative method. The lipidome quantitative kit can be used for quantitatively analyzing lipidomes of seven biological samples such as plasma, urine, cells, liver and excrement of human or animal sources as well as escherichia coli and arabidopsis rosette leaves, and can meet quantitative analysis requirements of lipidomes in different biological samples.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

Disclosed herein are aspects of a compound according to Formula (I) Y[-Z-Ao-X]y. The compound may have a structure according to Formula (II) or Formula (III). Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and / or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The invention relates to a lipid composition, which comprises a polymer lipid, and the polymer lipid is a compound with a structure as shown in a formula (I), or a pharmaceutically acceptable salt, an isotope variant, a tautomer or a stereoisomer thereof. The invention also provides a nanoparticle composition and a pharmaceutical composition comprising the lipid composition, and an application of the lipid composition in delivery of a load. The polymer lipid compound in the lipid composition can replace PEG lipid and has the advantages of biocompatibility, easiness in decomposition in vivo and no toxicity, so that a novel lipid delivery system is obtained.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

This invention discloses a lipid assembly loaded with 5-aminolevulinic acid and its preparation method. The lipid assembly is a hollow sphere with a core consisting of a hydrophilic phospholipid-chelating agent conjugate formed by chelation with a reactive phospholipid PEG reagent. The outer layer of the phospholipid-chelating agent conjugate is loaded with 5-aminolevulinic acid via hydrazone bonds, and then combined with a radionuclide as an internal light source excitation photosensitizer. The lipid assembly is loaded with 5-ALA via hydrazone bonds. Utilizing the acid-sensitive bond-breaking characteristics of hydrazone bonds and the prodrug properties of 5-ALA, combined with a radionuclide labeled on the surface of the lipid assembly as an internal light source excitation photosensitizer, this invention can overcome the limitations of external light penetration depth in traditional photodynamic therapy, achieving deep PDT treatment. Combined with chemotherapy drugs, it can minimize the toxic side effects on normal tissues during the combined use of radionuclides and photosensitizers in targeted therapy.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

To provide a means effective in suppressing oxidative deterioration of fats and oils containing polyunsaturated fatty acid containing DHA and to provide a method capable of determining near olfactory sense of human being by specifying a component that becomes an index of oxidative deterioration of fat and acid containing DHA.SOLUTION: A lipid composition containing lipids composed of polyunsaturated fatty acids as constituent fatty acids, wherein a composition ratio of polyunsaturated fatty acids among all constituent fatty acids of the lipids is 15% or more, the moisture content is 600 ppm or less, perfluorooctanesulfonic acid is 0.1 ppb or less, and perfluorooctanoic acid is 0.1 ppb or less. It is preferable that the composition contains 2-(2-pentenyl)furan at less than 0.0095 ppm, and 2,4-heptadienal at less than 2.600 ppm.SELECTED DRAWING: None

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

Provided herein are novel ionizable cationic lipid compounds capable of assembling with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids, that are capable of reducing aggregation to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group (-NRc-C (S)-NRd-) in the linker between the lipid group and the head group.

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

The invention discloses a macrophage-targeting lipid nanoparticle and application thereof in malignant tumor treatment, ID3 mRNA is delivered through the lipid nanoparticle, firstly, an ID3 sequence is subjected to codon optimization to improve the expression efficiency and stability of ID3 protein, and the core treatment effect is enhanced; the lipid composition and the targeting ligand of the nanoparticles are further optimized, and mannose modified PEG lipid material (DSPE-PEG2000-Mannose) is specifically combined with the CD206 receptor on the surface of the macrophage, so that the targeting property and the transfection efficiency of the delivery system are remarkably improved. The ID3 mRNA is delivered to the macrophages by utilizing the lipid nanoparticles of the targeted macrophages, so that the tumor cells can be effectively swallowed and killed, the in-situ treatment of pancreatic cancer is realized, and better tumor inhibition and immune activation effects are achieved.

The invention discloses a production process of lipid nanoparticles entrapped with weak-acid and weak-hydrophobicity small molecule drugs, which comprises the following steps: S1, preparing a water phase and an organic phase, the organic phase comprising a lipid organic phase and a drug organic phase; s2, under an ultrasonic condition, successively mixing the water phase, the drug organic phase and the lipid organic phase in a microreactor through a microfluidic technology to form lipid nanoparticles, so as to obtain a crude sample containing the lipid nanoparticles; s3, diluting the crude sample by using a PBS (Phosphate Buffer Solution), and standing to obtain a sample diluent; s4, the sample diluent is subjected to ultrafiltration concentration, a concentrated sample is obtained, and a lipid nanoparticle product loaded with the medicine components is obtained. By adjusting the mixing time of the lipid component phase and other two-phase solutions, the drug precipitation rate and the lipid component precipitation rate are flexibly regulated and controlled, the drug encapsulation efficiency is effectively improved, and industrial production is facilitated.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value..

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present application relates to the technical field of biotechnology, more particularly to a biomarker for distinguishing benign biliary disease and cholangiocarcinoma and application thereof. The biomarker for distinguishing benign biliary disease and cholangiocarcinoma provided by the present application comprises 20 kinds of lipids and / or 5 kinds of polypeptides, and the single lipid group or single polypeptide group is used as a biomarker to distinguish benign biliary disease and cholangiocarcinoma, which has high sensitivity. When the lipid group and the polypeptide group are used as multi-group biomarkers, the sensitivity and accuracy of the discrimination can be further improved. In addition, the biomarker combination provided by the present application exists in serum, which is more suitable for non-invasive collection. The reagent or kit prepared based on the biomarker combination is more convenient for popularization and use. The risk prediction model for benign biliary disease and cholangiocarcinoma constructed based on the above biomarker has higher accuracy compared with the existing CA19-9 marker method, whether it is a single omics model or a double omics model.